SCHEMBL21332750

SCHEMBL21332750

OC1CCc2ccc(Br)nc21

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063983 0.89 ACHE (0.38) ACHE
SCHEMBL24490883 0.81 ACHE (0.30) ACHE
SCHEMBL845773 0.77 HTR2A (0.33) ACHE
SCHEMBL23376849 0.77 HTR2A (0.36)
SCHEMBL15833700 0.74 IDO1 (0.30)
SCHEMBL19151680 0.73 MTNR1A (0.33) ACHE
SCHEMBL21349676 0.73 HTR2C (0.32)
SCHEMBL5117771 0.72
SCHEMBL31598495 0.72 MEN1 (0.44) ACHE
SCHEMBL22852087 0.71 CHRM4 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2024-11-28 US disclosed
WO-2023125944-A1 COMPOUND CONTAINING HETEROCYCLIC RING 正大天晴药业集团股份有限公司 2023-07-06 WO disclosed
CN-112142748-B Pyrazolopyrimidine compound, and preparation method and application thereof 上海医药集团股份有限公司 2023-07-04 CN disclosed
WO-2023083194-A1 WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF 杭州格博生物医药有限公司 2023-05-19 WO disclosed
WO-2023030388-A1 5-FLUORO-7H-PYRROLO[2,3-D] PYRIMIDINES COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-03-09 WO disclosed
WO-2023016417-A1 1,2-DIHYDRO-3H-PYRAZOL[3,4-D]PYRIMIDIN-3-ONE COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-02-16 WO disclosed
WO-2023280180-A1 FUSED RING COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-01-12 WO disclosed
US-20220324868-A1 Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-10-13 US disclosed
EP-4008719-A2 PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2022-06-08 EP disclosed
EP-4008719-A2 PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2022-06-08 EP disclosed
US-11261192-B2 Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones RECURIUM IP HOLDINGS, LLC (US) 2022-03-01 US disclosed
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2022-01-27 US disclosed
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2022-01-27 US disclosed
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2021-05-13 US disclosed
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2021-05-13 US disclosed
EP-3762385-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES Recurium IP Holdings, LLC (US) 2021-01-13 EP disclosed
WO-2020259724-A2 PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR 上海医药集团股份有限公司 2020-12-30 WO disclosed
WO-2019173082-A1 SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES Zeno Royalties & Milestones, LLC (US) 2019-09-12 WO disclosed
WO-2019173082-A1 SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES Zeno Royalties & Milestones, LLC (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11261192-B2 Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones MKI67, BRCA1, CCNI ACHE 4774/4885
US-20220324868-A1 Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor WEE1, WEE2, WASF2 ACHE 3967/4885
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI ACHE 4774/4885
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI ACHE 4774/4885
US-20240391924-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI ACHE 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.